Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue (2010 - 2011)
Madrigal Pharmaceuticals' (MDGL) quarterly Current Deferred Revenue came in at $3.3 million in Q3 2011, down 25.71% on a QoQ basis from $4.4 million in Q2 2011.
Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue (2010 - 2011) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 2 years of Current Deferred Revenue data on file, last reported at $3.3 million in Q3 2011.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $3.3 million in Q3 2011; TTM through Sep 2011 was $3.3 million, a N/A change from a year earlier, with the FY2010 full-year figure at $4.6 million, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2011 stood at $3.3 million, down from $4.4 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for MDGL reached as high as $4.6 million in Q4 2010 and fell as low as $3.3 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 15.54 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 3.30 Mn |
| Jun 30, 2011 | 4.45 Mn |
| Dec 31, 2010 | 4.57 Mn |